Antibiotic Susceptibility Testing Market

ID: MRFR/HC/25219-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026
Antibiotic Susceptibility Testing Market Research Report: Size, Share, Trend Analysis By Sample Type (Blood Culture, Urine Culture, Pus Culture, Sputum Culture, Cerebrospinal Fluid Culture, Other Sample Types), By Pathogen Type (Gram-Positive Bacteria, Gram-Negative Bacteria, Anaerobic Bacteria, Mycobacteria, Fungi, Parasites), By Test Method (Disk Diffusion, Automated Susceptibility Testing Systems, Agar Dilution Method, Microdilution Method, Molecular Susceptibility Testing) - Growth Outlook & Industry Forecast 2025 To 2035
Antibiotic Susceptibility Testing Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.53%
2024 Market Size$ 3.79 Billion
2025 Market Size$ 4.04 Billion
2035 Market Size$ 7.6 Billion
Key Players
Thermo Fisher Scientific
BD
bioMerieux
Abbott Laboratories
Roche Diagnostics
Siemens Healthineers
Trends
  • Technological Advancements
  • Regulatory Focus on Antibiotic Resistance
  • Shift Towards Personalized Medicine
Opportunities
  • Rising Incidence of Antibiotic Resistance
  • Technological Innovations in Testing Methods
  • Increased Focus on Infection Control Practices
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Sample Type (USD Billion)
      1. 4.1.1 Blood Culture
      2. 4.1.2 Urine Culture
      3. 4.1.3 Pus Culture
      4. 4.1.4 Sputum Culture
      5. 4.1.5 Cerebrospinal Fluid Culture
      6. 4.1.6 Other Sample Types
    2. 4.2 Healthcare, BY Pathogen Type (USD Billion)
      1. 4.2.1 Gram-Positive Bacteria
      2. 4.2.2 Gram-Negative Bacteria
      3. 4.2.3 Anaerobic Bacteria
      4. 4.2.4 Mycobacteria
      5. 4.2.5 Fungi
      6. 4.2.6 Parasites
    3. 4.3 Healthcare, BY Test Method (USD Billion)
      1. 4.3.1 Disk Diffusion
      2. 4.3.2 Automated Susceptibility Testing Systems
      3. 4.3.3 Agar Dilution Method
      4. 4.3.4 Microdilution Method
      5. 4.3.5 Molecular Susceptibility Testing
    4. 4.4 Healthcare, BY End User (USD Billion)
      1. 4.4.1 Hospitals
      2. 4.4.2 Clinical Laboratories
      3. 4.4.3 Diagnostic Centers
      4. 4.4.4 Research Centers
      5. 4.4.5 Pharmaceutical Companies
    5. 4.5 Healthcare, BY Application (USD Billion)
      1. 4.5.1 Infectious Disease Diagnosis
      2. 4.5.2 Antimicrobial Stewardship
      3. 4.5.3 Research and Development
      4. 4.5.4 Clinical Trials
      5. 4.5.5 Surveillance and Infection Control
    6. 4.6 Healthcare, BY Region (USD Billion)
      1. 4.6.1 North America
        1. 4.6.1.1 US
        2. 4.6.1.2 Canada
      2. 4.6.2 Europe
        1. 4.6.2.1 Germany
        2. 4.6.2.2 UK
        3. 4.6.2.3 France
        4. 4.6.2.4 Russia
        5. 4.6.2.5 Italy
        6. 4.6.2.6 Spain
        7. 4.6.2.7 Rest of Europe
      3. 4.6.3 APAC
        1. 4.6.3.1 China
        2. 4.6.3.2 India
        3. 4.6.3.3 Japan
        4. 4.6.3.4 South Korea
        5. 4.6.3.5 Malaysia
        6. 4.6.3.6 Thailand
        7. 4.6.3.7 Indonesia
        8. 4.6.3.8 Rest of APAC
      4. 4.6.4 South America
        1. 4.6.4.1 Brazil
        2. 4.6.4.2 Mexico
        3. 4.6.4.3 Argentina
        4. 4.6.4.4 Rest of South America
      5. 4.6.5 MEA
        1. 4.6.5.1 GCC Countries
        2. 4.6.5.2 South Africa
        3. 4.6.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Thermo Fisher Scientific (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 BD (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 bioMerieux (FR)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Abbott Laboratories (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Roche Diagnostics (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Siemens Healthineers (DE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Danaher Corporation (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Cepheid (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Hologic (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY SAMPLE TYPE
    4. 6.4 US MARKET ANALYSIS BY PATHOGEN TYPE
    5. 6.5 US MARKET ANALYSIS BY TEST METHOD
    6. 6.6 US MARKET ANALYSIS BY END USER
    7. 6.7 US MARKET ANALYSIS BY APPLICATION
    8. 6.8 CANADA MARKET ANALYSIS BY SAMPLE TYPE
    9. 6.9 CANADA MARKET ANALYSIS BY PATHOGEN TYPE
    10. 6.10 CANADA MARKET ANALYSIS BY TEST METHOD
    11. 6.11 CANADA MARKET ANALYSIS BY END USER
    12. 6.12 CANADA MARKET ANALYSIS BY APPLICATION
    13. 6.13 EUROPE MARKET ANALYSIS
    14. 6.14 GERMANY MARKET ANALYSIS BY SAMPLE TYPE
    15. 6.15 GERMANY MARKET ANALYSIS BY PATHOGEN TYPE
    16. 6.16 GERMANY MARKET ANALYSIS BY TEST METHOD
    17. 6.17 GERMANY MARKET ANALYSIS BY END USER
    18. 6.18 GERMANY MARKET ANALYSIS BY APPLICATION
    19. 6.19 UK MARKET ANALYSIS BY SAMPLE TYPE
    20. 6.20 UK MARKET ANALYSIS BY PATHOGEN TYPE
    21. 6.21 UK MARKET ANALYSIS BY TEST METHOD
    22. 6.22 UK MARKET ANALYSIS BY END USER
    23. 6.23 UK MARKET ANALYSIS BY APPLICATION
    24. 6.24 FRANCE MARKET ANALYSIS BY SAMPLE TYPE
    25. 6.25 FRANCE MARKET ANALYSIS BY PATHOGEN TYPE
    26. 6.26 FRANCE MARKET ANALYSIS BY TEST METHOD
    27. 6.27 FRANCE MARKET ANALYSIS BY END USER
    28. 6.28 FRANCE MARKET ANALYSIS BY APPLICATION
    29. 6.29 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE
    30. 6.30 RUSSIA MARKET ANALYSIS BY PATHOGEN TYPE
    31. 6.31 RUSSIA MARKET ANALYSIS BY TEST METHOD
    32. 6.32 RUSSIA MARKET ANALYSIS BY END USER
    33. 6.33 RUSSIA MARKET ANALYSIS BY APPLICATION
    34. 6.34 ITALY MARKET ANALYSIS BY SAMPLE TYPE
    35. 6.35 ITALY MARKET ANALYSIS BY PATHOGEN TYPE
    36. 6.36 ITALY MARKET ANALYSIS BY TEST METHOD
    37. 6.37 ITALY MARKET ANALYSIS BY END USER
    38. 6.38 ITALY MARKET ANALYSIS BY APPLICATION
    39. 6.39 SPAIN MARKET ANALYSIS BY SAMPLE TYPE
    40. 6.40 SPAIN MARKET ANALYSIS BY PATHOGEN TYPE
    41. 6.41 SPAIN MARKET ANALYSIS BY TEST METHOD
    42. 6.42 SPAIN MARKET ANALYSIS BY END USER
    43. 6.43 SPAIN MARKET ANALYSIS BY APPLICATION
    44. 6.44 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE
    45. 6.45 REST OF EUROPE MARKET ANALYSIS BY PATHOGEN TYPE
    46. 6.46 REST OF EUROPE MARKET ANALYSIS BY TEST METHOD
    47. 6.47 REST OF EUROPE MARKET ANALYSIS BY END USER
    48. 6.48 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    49. 6.49 APAC MARKET ANALYSIS
    50. 6.50 CHINA MARKET ANALYSIS BY SAMPLE TYPE
    51. 6.51 CHINA MARKET ANALYSIS BY PATHOGEN TYPE
    52. 6.52 CHINA MARKET ANALYSIS BY TEST METHOD
    53. 6.53 CHINA MARKET ANALYSIS BY END USER
    54. 6.54 CHINA MARKET ANALYSIS BY APPLICATION
    55. 6.55 INDIA MARKET ANALYSIS BY SAMPLE TYPE
    56. 6.56 INDIA MARKET ANALYSIS BY PATHOGEN TYPE
    57. 6.57 INDIA MARKET ANALYSIS BY TEST METHOD
    58. 6.58 INDIA MARKET ANALYSIS BY END USER
    59. 6.59 INDIA MARKET ANALYSIS BY APPLICATION
    60. 6.60 JAPAN MARKET ANALYSIS BY SAMPLE TYPE
    61. 6.61 JAPAN MARKET ANALYSIS BY PATHOGEN TYPE
    62. 6.62 JAPAN MARKET ANALYSIS BY TEST METHOD
    63. 6.63 JAPAN MARKET ANALYSIS BY END USER
    64. 6.64 JAPAN MARKET ANALYSIS BY APPLICATION
    65. 6.65 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE
    66. 6.66 SOUTH KOREA MARKET ANALYSIS BY PATHOGEN TYPE
    67. 6.67 SOUTH KOREA MARKET ANALYSIS BY TEST METHOD
    68. 6.68 SOUTH KOREA MARKET ANALYSIS BY END USER
    69. 6.69 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    70. 6.70 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE
    71. 6.71 MALAYSIA MARKET ANALYSIS BY PATHOGEN TYPE
    72. 6.72 MALAYSIA MARKET ANALYSIS BY TEST METHOD
    73. 6.73 MALAYSIA MARKET ANALYSIS BY END USER
    74. 6.74 MALAYSIA MARKET ANALYSIS BY APPLICATION
    75. 6.75 THAILAND MARKET ANALYSIS BY SAMPLE TYPE
    76. 6.76 THAILAND MARKET ANALYSIS BY PATHOGEN TYPE
    77. 6.77 THAILAND MARKET ANALYSIS BY TEST METHOD
    78. 6.78 THAILAND MARKET ANALYSIS BY END USER
    79. 6.79 THAILAND MARKET ANALYSIS BY APPLICATION
    80. 6.80 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE
    81. 6.81 INDONESIA MARKET ANALYSIS BY PATHOGEN TYPE
    82. 6.82 INDONESIA MARKET ANALYSIS BY TEST METHOD
    83. 6.83 INDONESIA MARKET ANALYSIS BY END USER
    84. 6.84 INDONESIA MARKET ANALYSIS BY APPLICATION
    85. 6.85 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE
    86. 6.86 REST OF APAC MARKET ANALYSIS BY PATHOGEN TYPE
    87. 6.87 REST OF APAC MARKET ANALYSIS BY TEST METHOD
    88. 6.88 REST OF APAC MARKET ANALYSIS BY END USER
    89. 6.89 REST OF APAC MARKET ANALYSIS BY APPLICATION
    90. 6.90 SOUTH AMERICA MARKET ANALYSIS
    91. 6.91 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE
    92. 6.92 BRAZIL MARKET ANALYSIS BY PATHOGEN TYPE
    93. 6.93 BRAZIL MARKET ANALYSIS BY TEST METHOD
    94. 6.94 BRAZIL MARKET ANALYSIS BY END USER
    95. 6.95 BRAZIL MARKET ANALYSIS BY APPLICATION
    96. 6.96 MEXICO MARKET ANALYSIS BY SAMPLE TYPE
    97. 6.97 MEXICO MARKET ANALYSIS BY PATHOGEN TYPE
    98. 6.98 MEXICO MARKET ANALYSIS BY TEST METHOD
    99. 6.99 MEXICO MARKET ANALYSIS BY END USER
    100. 6.100 MEXICO MARKET ANALYSIS BY APPLICATION
    101. 6.101 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE
    102. 6.102 ARGENTINA MARKET ANALYSIS BY PATHOGEN TYPE
    103. 6.103 ARGENTINA MARKET ANALYSIS BY TEST METHOD
    104. 6.104 ARGENTINA MARKET ANALYSIS BY END USER
    105. 6.105 ARGENTINA MARKET ANALYSIS BY APPLICATION
    106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE
    107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATHOGEN TYPE
    108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST METHOD
    109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    111. 6.111 MEA MARKET ANALYSIS
    112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE
    113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY PATHOGEN TYPE
    114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY TEST METHOD
    115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY END USER
    116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE
    118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY PATHOGEN TYPE
    119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY TEST METHOD
    120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY END USER
    121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    122. 6.122 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE
    123. 6.123 REST OF MEA MARKET ANALYSIS BY PATHOGEN TYPE
    124. 6.124 REST OF MEA MARKET ANALYSIS BY TEST METHOD
    125. 6.125 REST OF MEA MARKET ANALYSIS BY END USER
    126. 6.126 REST OF MEA MARKET ANALYSIS BY APPLICATION
    127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
    128. 6.128 RESEARCH PROCESS OF MRFR
    129. 6.129 DRO ANALYSIS OF HEALTHCARE
    130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
    133. 6.133 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE)
    134. 6.134 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion)
    135. 6.135 HEALTHCARE, BY PATHOGEN TYPE, 2024 (% SHARE)
    136. 6.136 HEALTHCARE, BY PATHOGEN TYPE, 2024 TO 2035 (USD Billion)
    137. 6.137 HEALTHCARE, BY TEST METHOD, 2024 (% SHARE)
    138. 6.138 HEALTHCARE, BY TEST METHOD, 2024 TO 2035 (USD Billion)
    139. 6.139 HEALTHCARE, BY END USER, 2024 (% SHARE)
    140. 6.140 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    141. 6.141 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    142. 6.142 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.2.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.2.5 BY APPLICATION, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.3.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.3.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.3.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.3.5 BY APPLICATION, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.4.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.4.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.4.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.4.5 BY APPLICATION, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.5.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.5.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.5.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.5.5 BY APPLICATION, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.6.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.6.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.6.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.6.5 BY APPLICATION, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.7.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.7.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.7.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.7.5 BY APPLICATION, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.8.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.8.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.8.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.8.5 BY APPLICATION, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.9.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.9.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.9.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.9.5 BY APPLICATION, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.10.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.10.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.10.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.10.5 BY APPLICATION, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.11.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.11.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.11.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.11.5 BY APPLICATION, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.12.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.12.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.12.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.12.5 BY APPLICATION, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.13.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.13.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.13.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.13.5 BY APPLICATION, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.14.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.14.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.14.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.14.5 BY APPLICATION, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.15.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.15.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.15.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.15.5 BY APPLICATION, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.16.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.16.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.16.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.16.5 BY APPLICATION, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.17.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.17.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.17.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.17.5 BY APPLICATION, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.18.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.18.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.18.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.18.5 BY APPLICATION, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.19.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.19.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.19.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.19.5 BY APPLICATION, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.20.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.20.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.20.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.20.5 BY APPLICATION, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.21.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.21.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.21.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.21.5 BY APPLICATION, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.22.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.22.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.22.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.22.5 BY APPLICATION, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.23.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.23.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.23.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.23.5 BY APPLICATION, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.24.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.24.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.24.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.24.5 BY APPLICATION, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.25.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.25.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.25.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.25.5 BY APPLICATION, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.26.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.26.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.26.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.26.5 BY APPLICATION, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.27.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.27.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.27.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.27.5 BY APPLICATION, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.28.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.28.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.28.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.28.5 BY APPLICATION, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.29.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.29.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.29.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.29.5 BY APPLICATION, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
      2. 7.30.2 BY PATHOGEN TYPE, 2025-2035 (USD Billion)
      3. 7.30.3 BY TEST METHOD, 2025-2035 (USD Billion)
      4. 7.30.4 BY END USER, 2025-2035 (USD Billion)
      5. 7.30.5 BY APPLICATION, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Antibiotic Susceptibility Testing Market Segmentation

Antibiotic Susceptibility Testing Market By Sample Type (USD Billion, 2025-2035)

  • Blood Culture
  • Urine Culture
  • Pus Culture
  • Sputum Culture
  • Cerebrospinal Fluid Culture
  • Other Sample Types

Antibiotic Susceptibility Testing Market By Pathogen Type (USD Billion, 2025-2035)

  • Gram-Positive Bacteria
  • Gram-Negative Bacteria
  • Anaerobic Bacteria
  • Mycobacteria
  • Fungi
  • Parasites

Antibiotic Susceptibility Testing Market By Test Method (USD Billion, 2025-2035)

  • Disk Diffusion
  • Automated Susceptibility Testing Systems
  • Agar Dilution Method
  • Microdilution Method
  • Molecular Susceptibility Testing

Antibiotic Susceptibility Testing Market By End User (USD Billion, 2025-2035)

  • Hospitals
  • Clinical Laboratories
  • Diagnostic Centers
  • Research Centers
  • Antibiotic Susceptibility Testing Market Companies

Antibiotic Susceptibility Testing Market By Application (USD Billion, 2025-2035)

  • Infectious Disease Diagnosis
  • Antimicrobial Stewardship
  • Research and Development
  • Clinical Trials
  • Surveillance and Infection Control

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.